{
"@context": "https://schema.org",
"@type": "Article",
"headline": "Vision Loss Associated With Ozempic, Mounjaro, And Other GLP-1 Drugs",
"url": "https://www.lexblog.com/2026/10/16/vision-loss-associated-with-ozempic-mounjaro-and-other-glp-1-drugs/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-AWH04Z15",
"url": "https://www.lexblog.com/lib/AWH04Z15/"
},
"datePublished": "2026-10-16T20:01:54-04:00",
"dateModified": "2026-10-16T20:01:54-04:00",
"author": {
"@type": "Person",
"name": "Tom Lamb"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Law Offices of Thomas J. Lamb, P.A."
},
"organizationScope": "at-publication",
"isPartOf": "Drug Injury Watch",
"about": "Class Action & Mass Torts · Food, Drug & Agriculture · Personal Injury",
"sourceUrl": "https://drug-injury.com/2026/10/16/vision-loss-associated-with-ozempic-mounjaro/",
"sourceStability": "may-move"
}